Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis
DUBLIN, January 31, 2014 /PRNewswire/ –
Research and Markets (
http://www.researchandmarkets.com/research/xvxqgs/liver_cancer) have announced the
addition of the “Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis”
[http://www.researchandmarkets.com/research/xvxqgs/liver_cancer ] report to their
This report offers a unique therapeutic assessment and in-depth market and pipeline
analysis, providing a view of the hepatocellular carcinoma (liver cancer) market not
available elsewhere. The purpose of this report is to give an extensive overview of the
current and future liver cancer market, the activities of the key market players and the
issues surrounding drug development.
This report provides the pharmaceutical industry with a therapeutic assessment,
pipeline analysis, and unique insight into the current clinical trial environment for the
hepatocellular carcinoma (HCC) market.
HCC is the fifth most common cancer diagnosed globally in men, is the third most
common cause of cancer death, and because only one systemic therapy is available, remains
a highly underserved disease, explained Andrew Schafer, President of ISR. With high
incidence and morbidity rates and a lack of available effective therapies, significant
commercial opportunity exists for this orphan drug class.
To support this opportunity, ISR’s newest report provides a thorough disease overview,
discusses major and emerging markets, and compiles an analysis of ongoing and recently
completed HCC trials registered on ClinicalTrials.gov to shed light on trial activity
(reported in aggregate and by industry sponsors).
With this report, sponsors can learn how products in the pipeline could compete in
this market, identify strategic development opportunities, plan global clinical trial and
market access strategies, and assess the competition with a full analysis of companies
participating in this market, Schafer explained.
Additionally, ISR’s report provides a thorough analysis of 10 products currently in
early and late phase development that could result in promising new therapies.
Signal transduction pathways involved in tumor cell proliferation, resistance to
apoptosis, stimulation of angiogenesis, invasiveness, and metastasis have been implicated
in HCC and, therefore, are interesting targets for new therapies, Schafer explained.
Key Topics Covered:
Copyright and Usage Guidelines Table of Abbreviations Table of Definitions Infographic
Chapter 1 Hepatocellular Carcinoma Overview
Chapter 2 Commercial Rationale
Chapter 3 Environmental Analysis
Chapter 4 Clinical Development Pipeline
Chapter 5 Clinical Trial Environment
Chapter 6 Country Profiles
For more information visit
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets